ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories operating income 1985–2026

Abbott Laboratories's operating income in Q3 FY2026, the three months to 30 September 2026, was 1.48B USD, down 28.2% on the same quarter a year before. Abbott Laboratories's operating income over the last twelve months was 7.35B USD, down 5.6% on the twelve months before. In fiscal year 2025 it was 8.05B USD, up 17.9% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Operating income

Operating income · +10.6% a year over 10 yearsOperating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 20267.35B-5.60%15.24%27.55B57.12%9.71B
FY202531 Dec 20258.05B+17.92%18.16%24.61B55.51%11.92B
FY202431 Dec 20246.83B+6.06%16.27%21.33B50.83%10.83B
FY202331 Dec 20236.44B-23.04%16.04%20.04B49.96%10.61B
FY202231 Dec 20228.36B-9.11%19.16%22.32B51.14%11.89B
FY202131 Dec 20219.20B+73.88%21.36%23.21B53.89%12.16B
FY202031 Dec 20205.29B+15.25%15.29%17.38B50.21%9.00B
FY201931 Dec 20194.59B+19.43%14.39%16.69B52.32%7.91B
FY201831 Dec 20183.84B+94.93%12.57%15.82B51.75%6.88B
FY201731 Dec 20171.97B-39.30%7.20%13.07B47.70%6.13B
FY201631 Dec 20163.25B+10.17%15.58%11.24B53.92%3.07B
FY201531 Dec 20152.95B+1.13%14.45%10.96B53.71%4.83B
FY201431 Dec 20142.92B+35.88%14.40%10.49B51.81%4.23B
FY201331 Dec 20132.15B+6.93%9.82%9.86B45.12%3.81B
FY201231 Dec 20122.01B-70.66%5.03%10.85B27.22%3.50B
FY201131 Dec 20116.84B-2.97%17.61%23.44B60.33%9.26B
FY201031 Dec 20107.05B+7.31%20.05%20.59B58.56%9.14B
FY200931 Dec 20096.57B+7.91%21.36%17.62B57.27%9.49B
FY200831 Dec 20086.09B+23.12%20.62%17.04B57.72%8.22B
FY200731 Dec 20074.95B+14.05%19.08%14.59B56.29%6.92B
FY200631 Dec 20064.34B-6.74%19.29%12.84B57.14%4.25B
FY200531 Dec 20054.65B+11.30%20.81%11.87B53.14%6.22B
FY200431 Dec 20044.18B+40.46%21.23%10.80B54.86%5.61B
FY200331 Dec 20032.97B-5.65%15.11%10.21B51.86%4.20B
FY200231 Dec 20023.15B+66.41%17.82%9.18B51.90%4.30B
FY200131 Dec 20011.89B-44.30%11.63%8.54B52.42%4.39B
FY200031 Dec 20003.40B+7.98%24.74%7.51B54.61%4.23B
FY199931 Dec 19993.15B+1.01%23.90%7.20B54.64%3.98B
FY199831 Dec 19983.12B+9.38%24.99%7.08B56.77%3.90B
FY199731 Dec 19972.85B+8.92%23.99%6.84B57.54%3.56B
FY199631 Dec 19962.62B+9.83%23.76%6.28B57.03%3.30B
FY199531 Dec 19952.38B+11.13%23.80%5.69B56.79%2.95B
FY199431 Dec 19942.14B+11.45%23.42%5.16B56.38%2.65B
FY199331 Dec 19931.92B+26.08%22.88%4.72B56.18%2.41B
FY199231 Dec 19921.53B-1.99%19.43%4.77B60.81%1.95B
FY199131 Dec 19911.56B+10.73%22.64%4.12B59.85%1.94B
FY199031 Dec 19901.41B+15.14%22.83%3.60B58.53%1.76B
FY198931 Dec 19891.22B+10.82%22.70%3.13B58.19%1.53B
FY198831 Dec 19881.10B+9.58%22.32%2.85B57.82%1.37B
FY198731 Dec 19871.01B+14.47%22.92%2.53B57.65%1.25B
FY198631 Dec 1986878.60M+19.20%23.07%2.14B56.17%1.08B
FY198531 Dec 1985737.10M—21.94%1.82B54.19%892.90M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Abbott Laboratories's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.